JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Radiogenomics: a specific approach towards understanding breast, lung, brain and renal cancer

Urjaswee Dey

ABSTRACT

Radiogenomics is an emerging field that combines radiomics features extracted from medical imaging with genomic data to enhance cancer detection, diagnosis, and treatment including breast, lung, and renal cancer. By analysing the relationship between imaging features and genetic markers, radiogenomics aims to provide valuable insights into tumour behaviour, treatment response, and patient outcomes. Numerous imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and contrast-enhanced ultrasound (CEUS), can be used to identify and characterize breast cancer. Glioma can be cancerous (malignant) or non-cancerous (benign) brain tumor. Numerous benefits arise from the use of radiogenomics and radiomicomics in the management of gliomas, such as accurate prognosis prediction, exact diagnosis, evaluation of treatment response, and integration of genomic, imaging, and hemodynamic factors based on quantitative voxel-level MR image metrics. Radiomic analysis has demonstrated correlations between biological processes like angiogenesis, cell proliferation, apoptosis, and hypoxia and radiomic signals in the setting of lower-grade gliomas. About 80–85% of instances of lung cancer are non-small cell lung cancer (NSCLC), making it the most prevalent kind of the disease. The field of radiogenomics integrates genomic data with radiological characteristics from imaging modalities such as PET and CT to enhance the diagnosis and individualized care of patients with non-small cell lung cancer (NSCLC). Adverse outcomes have been connected to wild-type EGFR mutation, and poor survival has been linked to genomic characteristics derived from magnetic resonance imaging (MRI) and imaging. The goal of radiogenomics in clear cell renal cell carcinoma (ccRCC) is to use non-invasive imaging techniques to categorize tumors according to genetic and pathologic heterogeneity. Using particular radiopharmaceuticals, radioomics features from dynamic contrast-enhanced magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) can help distinguish benign from malignant renal lesions, assess the extent of the disease, and predict treatment response, tumor grade, and gene mutation status in patients with colorectal cancer (ccRCC). However, there are challenges in terms of data standardization, reproducibility, and the need for larger sample sizes and rigorous studies. Efforts are being made to overcome these limitations and establish reliable radiogenomic biomarkers through standardized protocols, validation in independent cohorts, and integration of automated feature extraction and AI

techniques. Overall, by offering insightful information on tumor biology and heterogeneity, radiogenomics offers an opportunity to provide tailored patient care and raise the efficacy of cancer treatment.

1.INTRODUCTION

With the growing field of personalized medicine, specific disease treatments and preventive methods can now be made available to groups of people according to their genetic composition, way of life, and surroundings. More accurate and customized genetic-based techniques including transcriptomics, the field of proteomics metabolomics, and genomics are employed to enable personalized therapy. In the world of cancer diagnosis, a groundbreaking approach known as radiogenomics has emerged, revolutionizing the way doctors detect and treat this devastating disease. By combining the power of radiology and genomics, radio genomics harnesses the potential of advanced imaging techniques to uncover valuable genetic information about tumors. Major cancers like breast cancer, renal cell carcinoma, small lung cell carcinoma, prostate cancer, and others can now be treated with better patient outcomes thanks to the innovative technique of integrating radiology and genomics. This allows for early cancer detection, treatment response prediction, and identification of potential genetic targets for therapy. [1]. To understand the power of radiogenomics, it is essential to grasp the relationship between genetics and radiology. Traditionally, radiology has been used to visualize and assess tumors based on their anatomical characteristics. However, with the advent of radiogenomics, the focus has shifted to analyzing the genetic information contained within these images. By examining certain patterns and features in medical imaging data, researchers can uncover genetic markers that provide crucial insights into the behavior and prognosis of tumors. This data enables doctors to choose the right treatment plan, which may include chemotherapy, radiation therapy, surgery, or a mix of these two options. By this, researchers can deduce target-specific vulnerabilities and increase the chances of successful outcomes[2]. Additionally, radiogenomics can help predict the likelihood of a tumor spreading or metastasizing, enabling early intervention and proactive treatment strategies by identifying genetic markers associated with early stages of cancer development thus preventing disease progression whereas, traditional screening methods, such as mammography or computed tomography (CT) scans, can often detect tumors only after they have reached a certain size or become symptomatic. As radiogenomics can identify genetic markers, it can indicate or predict the treatment in response to the tumor which allows the patient to select the most appropriate therapy from the onset and prevent the process of trial-and-error undergoing multiple rounds of unnecessary chemotherapy or radiation therapy and showing side effects and hampering the overall treatment efficacy. [1]

A number of tools and resources have been created recently to help in radiogenomics research and clinical application. Advancing radiogenomics requires collaborative efforts between researchers, clinicians, and industry partners. Public-private partnerships can drive innovation and accelerate the translation of radiogenomics into clinical practice. By fostering collaboration, sharing resources, and promoting data sharing, these partnerships can overcome barriers and facilitate the adoption of radiogenomics in cancer care. Access to extensive imaging and genomic datasets, as well as carefully selected radiological and

histopathological imaging, is made possible by databases like The Cancer Imaging Archive (TCIA) and Genomic Data Commons (GDC), which are designed to meet specific research needs. Researchers can examine the connection between radiology and genomics by using imaging collections, which contain information about patient outcomes, treatment details, pathology, and expert analyses that are either provided or linked to when accessible. [3]. Furthermore, international collaborations can help establish global standards and guidelines for radiogenomics research and implementation. Initiatives like the Radiogenomics Consortium and the Quantitative Imaging Network (QIN) provide a wide aspect regarding image and data analysis of tumors and biomarkers to enhance treatment response methods. By pooling expertise and resources, these collaborations can drive progress and ensure the widespread adoption of radiogenomics in oncology.

METHODS

Tumor analysis using radiogenomic biomarkers

Both histological and inheritable tumor diversity have been noted in malignancies, and higher intra-tumor inheritable diversity conditions have been linked to unfavorable clinical outcomes. Radiogenomics and niche imaging are recently arising fields used for assessing tumor diversity. Radiomics is the high-throughput analysis of numerous form, edge, and texture parameters extracted from evaluations of medical images, such as MRI, CT, and PET scans. [4] These criteria give perceptivity into the phenotype of the tumour and its commerce with the medium. Conversely, radiogenomics investigates the connection between imaging characteristics and molecular variations present in towel samples by connecting radiomic criteria with genomics data.

The term "habitat imaging" describes the examination of discrete areas within a tumor, each exhibiting unique ratios of necrosis, edema, inflow, and cell viscosity. These different territories can give fresh radiomic features that contribute to the understanding of tumour diversity. Therefore, radiogenomics has an implicit significance in supporting the assessment of cancer complaint and determining the aggressiveness of cancer. By predicting medication response and potential resistance to treatment, radiogenomic analysis can also be utilized to guide treatment decisions for specific tumors. It can also be developed as a biomarker for oncological problems.

These crucial disciplines currently face a number of initial challenges, including as repeatability, the requirement for confirmation, standardization of imaging analysis, data communication, and therapeutic translatability. It is difficult to ensure reproducibility due to factors like poor study designs, high levels of specialized difficulty, info overfitting, inadequate result reporting, and variable confounding. Dimensionality reduction ways can help address the issue of overfitting, but standardization of tools for genomic profiling is still lacking. confirmation with prospectively collected independent cohorts is pivotal for vindicating statistical associations or biomarkers. still, retrospective confirmation studies are frequently hindered by the lack of intimately available radiomics data. Shared databases, such as the Cancer Imaging Archive (TCIA)

and the Cancer Genome Atlas (TCGA), can be invaluable repositories for verification. Sample size plays a significant part in the power of prophetic classifier models used in radiomics studies. Larger datasets give further statistical power, but acquiring a sufficiently sized sample set requires large databases and data participating capabilities across different spots. This highlights the significance of developing integrated intimately available databases that link images and uprooted features to clinical and molecular data. Image accession parameters differ extensively in clinical routine practice, making it grueling to compare results attained across different machines. Imaging protocol standardization, including image accession then post-processing, and robust segmentation algorithms, is necessary to insure thickness and reproducibility. Clinical translatability is still being explored in radiogenomics. The different scales at which imaging, genomics, and histopathology measure biology make it delicate to validate image diversity biomarkers against histopathology. Overall, addressing these obstacles is pivotal for the consummation of perfection oncology. [5]

Radiogenomics is a fleetly developing field of exploration targeted at relating imaging biomarkers to non-invasive genotyping. Varies databases of radiogenomic associations unravels imaging groups networks and oncology-wide gene pathways. Wrongly- defined excrescence perimeters and excrescence diversity can thereby be used as imaging biomarkers for glioma, non-small cell lung cancer, prognosticating high- threat inheritable tests in bone cancer and for assessing grade, stage, and invasiveness in renal cell melanoma. Quantitative imaging (QIN) involves the birth of quantitative parameters from medical images, similar as perfusion, prolixity, and texture features. These parameters give objective and quantitative measures of colorful imaging characteristics. These models can capture subtle variations in imaging characteristics that may be reflective of specific inheritable differences or pathway conditioning. Standardization of styles and confirmation in independent cohorts are necessary to insure the trust ability and generalizability of quantitative radiogenomic models. [6] Radiogenomics is designed to consolidate the understanding of excrescence biology and prisoner the natural excrescence diversity. The thing of radiogenomics is to develop imaging biomarkers that integrate both phenotypic and genotypic criteria. [2]

BREAST CANCER

Radiogenomics shows promise in arrangement, differential analysis, and forecast of breast cancer. It also reveals the connection between imaging features, molecular subgroups, and tumor molecular biomarkers. Radiogenomics can aid in the diagnosis and treatment of breast cancer in patients. Many researchers have collected data extracted from the tumor samples of patients suffering from breast cancer and examinations were conducted on different parameters. Thereby, concluding the use of radiogenomic biomarkers in prognosis of breast cancer. Radiogenomics research in breast cancer has focused on finding imaging surrogates for genomic markers as well as integrating imaging, genomic, and molecular data to create individualized biomarkers for disease characterization.

Radiogenomics combines imaging features with genomic data to improve breast cancer detection and treatment. There are various imaging modalities such as magnetic resonance imaging (MRI), method used is MR imaging, which is highly beneficial for screening of breast cancer since it has high sensitivity than mammography and ultrasoundas it can detect dence breast tissues which could possibily be ignored by other imaging modalities. Because it cannot measure the axilla or the elasticity of a lesion, automated breast ultrasound (ABUS) is used as a supplementary tool for breast cancer screening. [7] It can be complementary with mammography providing additional diagnosis such as BRCA1 and BRCA2 mutations and it's increasing risk. It can also detect atypical or benign features such as fibroadenoma (breast lumps) like masses in the axillary accessory breasts (AABs) reducing the risk of BC, this leads to enhanced detection rates [8]. Breast MR imaging evaluates enhanced kinetics for identifying benign kinetic features or abnormal patterns that indicate malignancy. The location of the tumour can also be derived, which can be likely be located in the immediate pre pectoral region, posterior part of the breast. MR imaging can effectively detect lesions in that area [9]. The majority of studies evaluated MRI features using the American College of Radiology-Breast Imaging Reporting and Data System (ACR-BIRADS) classification and dynamic contrast-enhanced (DCE) kinetic features, as well as apparent diffusion coefficient (ADC) values, which are a type of diffusion-weighted MRI that evaluates the magnitude of diffussion in water molecules within the tissue. [10]

Contrast-enhanced ultrasonography (CEUS) reveals enhancement patterns that aid in the identification of sentinel lymph node (SLN) status in breast cancer. It discusses the importance of SLN in determining clinical outcomes and the role of SLN biopsy in breast cancer treatment. With different selection critaria, data extraction and quality assesment, SLN can be diagnosed in BC patients [11] and computed tomography (CT). These imaging modalities are utilized to extract radiomic properties that can distinguish the important molecular aspects of breast cancer patients, including texture, morphologies, dynamic features, size, orientation, form, echo pattern, margin, calcifications, and vascular characteristics. [10]

Dynamic contrast-enhanced MRI includes the inoculation of a contrast agent which enhances visualization and characterization of lesions or abnormalities in the breast and determine their malignant potential. One study used DCE-RI to extract a multiparametric imaging phenotype vector from tumour regions, which was then used to classify tumors at low, medium, and high risk of recurrence. With the combination of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and RNA-sequencing and association of long noncoding RNA (lncRNA) expression and other gene expression we can recognize imaging features that can indicate breast cancer (BC) subtypes and prognosis.[12] Certain gene expressions were found such as CHEK1, TTK, CDC45, BUB1B, PLK1, E2F1, CDC20, and CDC25A. Genes involved with the cell cycle pathway were also found associated with the imaging features.[13] Such other characteristic can decide the accuracy of breast cancer diagnosis and therapy by detecting imaging aspects that indicate genetic changes associated with tumor morphologies, lymph node status, hormone receptor status, HER2 status, Ki67 expression, and molecular subtypes. [10]. The prediction accuracy achieved AUC (Area Under the Curve) values which represents the ability of Multiview convolutional neural network (CNN) is observed for MammaPrint, OncotypeDX and PAM50 samples. A radiogenomic signature was used to predict

OncotypeDX and PAM50 recurrence scores in breast cancer patients using digital mammograms. The prediction accuracy achieved AUC (Area Under the Curve) values which represents the ability of Multiview convolutional neural network (CNN) is observed for MammaPrint, OncotypeDX and PAM50 samples. A radiogenomic signature was used to predict OncotypeDX and PAM50 recurrence scores in breast cancer patients using digital mammograms. [14]

The research conducted with context to radiogenomic biomarkers are limited primarily due to insufficient number of patients, inconsistent radiogenomic methods, lack of optimization of acquisition parameter, need for larger sample size and rigorous studies, heterogeneity of studies.[10] The limitation of radiogenomic biomarkers in breast cancer is primarily related to the challenges associated with obtaining representative tissue samples for molecular characterization. Additionally, large-scale genomic profiling is costly and requires complex data analysis and interpretation plus, it's difficult to store high volumes of data. These restrictions impede the establishment of prospective clinical studies in radiogenomics. Furthermore, the existing databases linking imaging data to genetic profile are limited. Standardization of imaging and biochemical techniques, as well as the selection of imaging features, is necessary for stable and reproducible radiogenomic biomarkers.[15] To overcome these limitations, efforts are needed to establish standardized perspective studies with large cohorts and comprehensive biological sample collections to ensure reliable results.

NSCLC

Non-small cell lung cancer (NSCLC) is a kind of lung cancer that develops in pulmonary tissues. It is the most prevalent kind of lung cancer, accounting for between 80 and 85% of cases. NSCLC is a wide term that includes three major subtypes: adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma. The prediction of non-small cell lung cancer (NSCLC) can vary depending on several factors, including the stage at diagnosis, subtype, overall health, and the effectiveness of the chosen treatment.[16] Radiogenomics has contributed to the prognosis of lung cancer by establishing associations between radiological features and genomic information. By analyzing the correlation between gene expressions and computed tomography (CT) and positron emission tomography (PET) image features, semantic annotations, gene mutation analyses (EGFR, KRAS, ALK), gene expression microarrays, and RNA sequencing data researchers have identified statistically significant pairwise correlations.[4] These correlations have provided insights into the prognostic significance of certain imaging features such as tumor size, edge shape, and sharpness. Accurate lung cancer diagnosis helps establish whether the cancer has spread to neighbouring lymph nodes or other organs, which is critical for staging the illness and predicting outcomes, allowing for the most appropriate treatment approach and customized care. It also aids in determining the degree and aggressiveness of the malignancy, allowing for better planning and guidance for procedures such as endobronchial ultrasonography or mediastinoscopy. [17] Overall, precise lung cancer diagnosis is critical to improving patient outcomes and optimizing treatment methods..[18]

Radiogenomics has also been used to create radiogenomic maps that depict the relationships between imaging features and molecular pathways, highlighting the role of genes like EGFR in lung cancer pathobiology.[19] Epidermal Growth Factor Receptor (EGFR) gene is a biomarker used for target therapy testing which could be obtained via invasive methods such as biopsy but usage of machine learning techniques and imaging phenotypes unsheathed from CT scans. Hence, semantic predictive model and combined ensembles methods do not provide propitious contribution towards predictive developed models.[20] PET image features from tumor 18F-fluorodeoxyglucose (FDG) uptake were linked to genetic mutations and oncogenic signalling pathways in patients with lung cancer. [21] The metabolic intensity of the tumour was also associated with specific genetic alterations. However, the findings' generalizability is restricted due to the small sample size and diversity in PET picture characteristics generated by various situations. [22] Annotations or marks on CT scans of regions of interest, such as anatomical features in the mediastinum, such as the lungs, airways, aortic arch, azygos vein, brachiocephalic veins, and others, including lymph nodes of various sizes. As a result, we provide a combination of U Net network and Mask R-CNN, which provide pixel-wise segmentation and instance identification, respectively. [18] Non-small cell lung cancer (NSCLC) carcinogenesis and biomarker discovery using microarray data analysis of gene and miRNA expression shows specific network analysis, including adherent junction, relaxin signalling pathway, and axon guidance. Genes like BIRC5, FGF2, RTKN2, SLIT3 and miRNA such as hsa-miR-9-5p, has-miR-196a-5p, hsa-miR-31-5p, hsa-miR-1, hsa-miR-218-5p, and hsa-miR-135a-5p were found and analysed.[23] miR-144-3p was considerably down-regulated in NSCLC tissues relative to healthy tissues. miR-144-3p expression is linked to clinical features such stage, lymph node metastases, and vascular invasion. Bioinformatics analysis identify possible miR-144-3p target genes in NSCLC, as well as enriched pathways including protein digestion and absorption and thyroid hormone signaling. Additionally, hub genes like as CEP55, E2F8, STIL, and TOP2A have been identified as possible miR-144-3p targets in NSCLC. [24] Combination of gene expression and clinical data forms a deep neural network which includes prognostic, well-known and novel that can precisely predict the overall survival of NSCLC patients. The integration of microarray and clinical data using the DNN showed better performance compared to other machine learning methods.[25]

Single-cell RNA sequencing (scRNA-seq) is also used to analyse the evolution of human lung cancer during targeted therapy. The molecular and immune variations before and after treatment highlights therapy-induced plasticity of cancer cells and tumour microenvironment. The scRNA-seq analysis identifies targetable oncogenes beyond those which are clinically detected and the presence of an alveolar cell signature in cancer cells surviving therapy and also the changes in the immune cell composition of the tumour microenvironment.[26] Upfront next-generation sequencing (NGS) is a practical and cost-effective way of diagnostic molecular profiling in an EGFR, TP53, and KRAS mutant-dominant population by detecting actionable changes. NGS demonstrates excellent sensitivity and specificity for detecting actionable alterations, such as EGFR, TP53, and KRAS mutations.[27]

The data was acquired from all of the aforementioned correlations, allowing for the identification of the association between tumor molecular and medical image characteristics, as well as the development and assessment of prognostic medical image biomarkers. These approaches have been used to predict overall survival (OS), disease-free survival (DFS), and therapy responsiveness in lung cancer patients. Furthermore, radiomics/radiogenomics has the ability to predict therapy response, progression-free survival(PFS), and overall survival (OS) using baseline imaging appearance. Overall, radiogenomics has the potential to guide more personalized patient care by providing valuable prognostic information in lung cancer. [19]

GLIOMA

Radiomics and radiogenomics are used extensively in the treatment of gliomas, which are primary brain excrescences. A glioma is an excrescence that develops in the brain or spinal cord. Gliomas are a common type of brain excrescence, making up about 33 of all brain excrescences. Gliomas can be cancerous(malignant) or non-cancerous (benign).[28] Application of quantitative voxel- position MR image criteria to offer precise opinion, prognosticate prognostic, and assess excrescence response to treatment. new radiomic and radiogenomic workflows and forms in sub-visual MR image processing also focuses on glioma operation. Radiomic features uprooted from pre-treatment MRI reviews can seize the extent of hypoxia in glioblastoma which is achieved by hypoxia enrichment score (HES) which is a radiogenomic study using microasssay expression data.[29] The hypoxia enrichment score (HES) is generated using single-sample Gene Set Enrichment Analysis (ssGSEA) on the genomic data of glioblastoma (GBM) cases. The HES values are used to categorize cases into low, medium, and high hypoxia groups. The HES serves as a surrogate marker of excrescence hypoxia and is used to probe its relationship with radiomic features and overall survival in GBM cases.[30] Hypoxia is a low oxygen condition and is the major reason of excrescence progression and poor prognostic in gliomas. A hypoxia danger model based on five hypoxia-related genes is used as a biomarker to predict overall survival; high hypoxia threat scores are linked with poor overall survival and reflect an immunosuppressive environment in glioma patients. Gene set enrichment analysis reveals that gene sets linked with high-threat groups are implicated in carcinogenesis and immunosuppressive signaling. [31] The threat score, grounded on the hypoxia- related long non-coding RNA(HRL) hand, is a potent marker for prognosticating the prognostic of LGG cases. A high threat score showing a poor prognostic, as indicated by the Kaplan- Meier analysis was observed in different groups of LGG cases, including different grades (II and III), age groups (≤ 45 times old and> 45 times old), and IDH mutant or wildtype cases. Multivariate Cox analysis verified that the threat score is a self-determining threat factor for LGG cases.[32] Using deep convolutional neural network (DCNN) to establish a malice evaluation model that can give further objective and accurate individual suggestions for grading gliomas. The issue of limited data is addressed by utilizing transfer literacy to transfer pretrained weights obtained from millions of natural pictures, as well as data addition methods to improve the number and diversity of training data. As a result, refining clinical care for CNS gliomas through the use of MRI information and machine literacy techniques. MRI- grounded radiomics can prognosticate molecular subtypes and assess prognostic value in glioma cases.[33] Machine literacy algorithms can develop single- layered radiomic

autographs and image emulsion models to prognosticate the position of IDH mutation, 1p/ 19q codeletion, and TERT protagonist mutation. This allows the vaticination of progression-free survival (PFS) and overall survival(zilches) grounded on the prophetic molecular groups and clinicopathologic data.[34] Some of the radiographic phenotypes associated with the IDH1 mutation in glioblastoma include small regions of improvement, a larger proportion of non-enhancing excrescence, excrescencies with low T1 signal intensity, suppressed T2- faculty signal intensity, well- defined excrescence perimeters, larger volume of abnormality on T2-ladened imaging, advanced mean regularized apparent prolixity measure(nADC), and advanced excrescence blood inflow. also, IDH1- mutant excrescences are more constantly set up in the anterior lobe.[35] Other radiomic features associated with IDH mutation include an anterior lobe position conterminous with the rostral extension of the side ventricles, an advanced mean apparent prolixity measure (ADC) value in prolixity imaging, lower relative cerebral blood volume (rCBV) values, advanced skewness and kurtosis, a larger portion of enhancing excrescence with supplementa improvement, and an infiltrative pattern of edema. These characteristics have been connected through vivid radiogenomic investigations, and they have demonstrated predictive utility in predicting the IDH mutational status in gliomas. [36]

The radiomic hand in patients with lower-grade gliomas (LGGs) was designed to be connected with a variety of natural processes, including hypoxia, angiogenesis, apoptosis, and cell growth. The radiomic analysis revealed that the high-threat phenotype was highly connected with oncogenic natural processes such as stem cell proliferation and angiogenesis, which may indicate the malice of high-risk LGGs. Furthermore, the radiogenomic study found that genes involved in multicellular creature development, such as SPRED1 and SPRED2, were strongly related with the radiomic threat score.[37] Imaging, genomic, and hemodynamic data obtained from non-enhancing areas of glioblastoma on multi-sequence enhanced MRI, such as relative cerebral blood volume and crossing of the midline, were shown to be related with poor survival. The wild-type EGFR mutation was likewise linked to poor survival in instances with a high relative cerebral blood volume. [29] A non-invasive imaging technique that uses cluster analysis of temporal elaboration (CAT) to integrate oxygen birth bit (OEF) based on quantitative vulnerability mapping and quantitative blood oxygen position-dependent magnitude (QSM qBOLD or QQ) measurements. By integrating CAT for QQ-grounded OEF mapping with dynamic discrepancy-enhanced (DCE) perfusion MRI, it is feasible to predict inheritable phenotypes and distinguish between various grades of glioma in a non-invasive way. [38] OEF values attained through this mapping fashion have shown significant differences between IDH1- shifted and wild- type excrescences, as well as between glioblastoma(GBM) with methylated and unmethylated MGMT protagonist. OEF and perfusion criteria have demonstrated fair performance in secerning between lower- grade glioma (LGG) and GBM, with OEF achieving the stylish performance.[37] Hemodynamic towel hand (HTS) system can be used to prognosticate IDH genotype in high- grade gliomas. HTS system has high vaticination capabilities for IDH mutation status and can give quantifiable territories associated with excrescence vascular diversity. rCBV levels in the regions may also differentiate IDH mutations from wild type in all three groups. The Kaplan-Meier survival analysis demonstrated that high rCBV levels in the low-angiogenic boosting excrescence niche were linked with shorter overall survival in GBM patients. [39] Advanced hemodynamic imaging exploration provides

promising imaging developments similar as discrepancy- enhanced ultrasound(CEUS), intravoxel incoherent stir(IVIM)- MRI, and gas modulation and BOLD imaging to round traditional excrescence grading by relating specific hemodynamic patterns in verbose gliomas to molecular and pathophysiological differences.[40] Mass Effect Deformation Heterogeneity (MEDH) is a radiomic point that quantifies the friction of per- voxel towel relegation bulks in the brain due to mass effect caused by glioblastoma(GBM). It measures the distortions in the cortical and subcortical structures of the brain, specifically within functionally eloquent areas. It's reckoned by aligning the GBM case's T1- ladened MRI to a strong atlas and calculating the friction of voxel-wise distortion bulks within anatomical structures. Advanced MEDH values indicate lesser diversity in towel relegation due to mass effect. Advanced MEDH in functionally expressive areas, particularly in the left semicircle, is related with poor survival in cases with right cerebral semicircle GBM.[41] The response- prolixity model with mass effect (RDM) provides the most accurate prognostications of excrescence growth, while the response- prolixity- advection model (RDAM) presents lower variation in its estimates of the prolixity measure and proliferation rate.[42] Mechanical parcels of the medium, similar as stiffness and fluid inflow dynamics, have been set up to impact complaint diversity and treatment resistance. Understanding these biophysical factors can help in designing further effective curatives and developing individual biomarkers. Implicit remedial targets include mechanosensitive ion channels and downstream signaling pathways associated with mechanotransduction.[43]

RENAL CANCER (ccRCC)

Clear cell renal cell carcinoma (ccRCC) is the most frequent kind of kidney cancer. Radiogenomics is a promising topic that integrates imaging-derived radiomic characteristics with genetic data to improve kidney cancer treatment. It aims to characterize excrescences predicated on heritable, epigenetic, and pathologic diversity using non- invasive imaging styles.[44] MR phenotype imaging, analogous as CT reviews can predict radiogenomic features associated to gene mutational status analogous as VHL, PBRM1, BAP1, SETD2, and KDM5C mutations, followed by gene expression and epigenetic features. mainly multiphasic, distinction- enhanced CT reviews are used as imaging modality of choice rather of predictive models for clinical issues, analogous as overall survival and response to treatment. This is primarily due to limitations analogous as small cohort sizes, variability in CT imaging quality, private excrescence segmentation, lack of standardized protocols for radiomic point birth, and the absence of consideration for intra- neoplasm diversity.[45] The use of radiogenomics can give objective interpretation of imaging, meliorate the opinion of renal lesions, needleworker treatment for individual cases, and contribute to clinical disquisition on renal carcinogenesis. future disquisition should concentrate on adding the size of cohorts, homogenizing protocols, and incorporating automated point birth and AI ways to overcome these limitations.[44] Radiomics is a quantitative image analysis fashion that involves the birth and analysis of multiple image features from reckoned tomography (CT) and glamorous resonance imaging (MRI) reviews. These features, analogous as histograms, textures, and shapes, are used to predict gene mutation status, excrescence grade, and treatment response in clear cell renal cell carcinoma (ccRCC) cases. Mixing radiomics with genomics,

transcriptomics, and proteomics data bettered the prognostic power of overall survival models compared to using any omics alone.[46] Machine knowledge (ML) and Deep knowledge (DL) algorithms have been considerably used in radiogenomics disquisition to anatomize radiomics features and prognosticate clinical issues in renal cancer. The MMDLM (multimodal deep knowledge model) showed great performance in predicting the prognostic of cases with clear- cell renal cell carcinoma(ccRCC). The model possess the capability to rank cases predicated on their survival times.[47] Machine knowledge algorithms, analogous as arbitrary timber (RF), grade boosting decision tree (GBDT), and extreme grade boosting (XGBoost), were used to establish predictive models predicated on radiomics features and omics dataThe high area under the Receiver Operating Characteristic (ROC) with (AUC) values demonstrated strong discriminative capabilities for OS, successfully stratifying patients into high- and low-risk groups with considerably varied survival concerns. Decision wind analysis (DCA) demonstrated that themulti- omics model handed more net benefit in predicting survival compared to radiomics and other single- omics models.[46] These algorithms compare radiomics features with heritable data to prognosticate mutation status, survival rates, complaint-specific survival(DSS) whose effect can be determined via the analysis of different variables included in nomograms that are race, commerce, Fuhram grade, pathological stage, surgical treatment, age at opinion, and nuptial status[48] , progression-free survival(PFS), and metastasis prophecy. Molecular Imaging (MI) ways, similar as Positron emigration tomography (PET/ CT) and prolixity- ladened imaging (DWI)- MRI, have been estimated as implicit biomarkers for renal cancer prognostic. Positron Emission Tomography/ reckoned Tomography (PET/ CT) with 89Zr- girentuximab is a non-invasive fashion which can prop in the opinion of clear cell renal cell melanoma(ccRCC) dubitation by confirm or count the presence of ccRCC, estimate the extent of the complaint, and separate it from other cancers and can guide clinical decision making in cases where there's query about the stylish medical treatment. It can help determine whether surgery, active surveillance, or systemic remedy is the most applicable coming step in the operation of ccRCC dubitation.[49] Positron emigration tomography/ reckoned tomography (PET/ CT) with prostate-specific membrane antigen (PSMA)- targeting radiopharmaceuticals has shown promising results in detecting clear cell renal cancer (ccRCC) lesions and differencing aggressive phenotypes leading to treatment revision in a significant chance of cases. Prospective multicentric studies are needed to further understand the role of PSMA-targeted PET/CT in ccRCC. [50] The use of FDG-PET in ccRCC (clear cell renal cell melanoma) is to possibly identify high-risk lesions. However, it is unable to discriminate between low-grade ccRCC and oncocytoma, as well as aggressive pRCC type I and low-grade ccRCC lesions from benign reality. Thus, FDG- PET isn't sufficient for definitive opinion and histopathological examination is still necessary for nasty subtypes with metastatic eventuality.[51]

Prolixity- ladened MRI (DW MRI) was used as part of the imaging protocol to assess the growth of ccRCC excrescences. The association between excrescence growth rate and volume replicating time was investigated using CT measurements and ADC voxel analysis and histograms, and colorful parameters such as quartiles, percentiles, mean, skewness, and kurtosis were determined from the histograms. The relationship between growth rate and volume doubling time and ADC histogram data was examined to determine the growth of the excrescence. [52] The eventuality of intravoxel incoherent stir (IVIM) analysis

in separating the donation of microvasculature from towel prolixity signal. Different imaging ways, similar as prolixity- ladened MRI with multiple b values and biexponential wind fit can distinguishing between benign and nasty renal lesions. IVIM analysis using a biexponential wind fit may be a promising fashion for assessing the pathological score of clear cell renal cell melanoma.[53] These imaging modalities can assess treatment response, prognosticate overall survival and estimate the presence of high- grade excrescences. A radiogenomic threat score can be deduced using CT imaging features and gene expression data. They employed multivariate retrogression to discover characteristics that predicted variance in supervised top element (SPC) gene expression analysis. The RSS showed a strong connection with microarray gene expression data and complaint-specific survival after controlling for stage, grade, and performance level. [45] The radiogeomic features were further reduced using the mRM system and named using Lariat analysis. These identified characteristics were paired with pass-through sections to create radiogenomics markers. To boost its trustworthiness, the biomarker was evaluated using the Mann-Whitney U test and ROC angles, which included clinical and pathological data. Univariate and multivariate analyses were used to discover rudiments linked to inheritable subsets in the excrescence medium. [54] Identification of new molecular subtypes in clear cell renal cell melanoma(ccRCC) is derived using colorful ways similar as correlation analysis, Cox retrogression, agreement clustering, and K- means clustering. membrane lipid metabolism in ccRCC vaticination is a lipid metabolic hand which was constructed using LASSO Cox retrogression, and a nomogram was generated to prognosticate survival chances for individual ccRCC cases.[55] They employed. Lariat-COX retrogression is used to detect prognostic radiomic characteristics and gene signatures. An RF algorithm was also employed to merge these characteristics and create a radiogenomic prognostic model. This approach outperformed a model based primarily on radiomic characteristics, demonstrating enhanced delicacy in predicting survival at 1, 3, and 5 times.[45] A research found that a nine-gene hand, connected using the LASSO Cox retrogression model, may be employed as an independent predictive predictor for stage III ccRCC patients. The C- indicator of the risk group (nine- gene classifier) was advanced than the C- indicator of the three clinical factors combined, indicating that the gene hand had a better prophetic power.[56] The part of the epigenetic hand is to identify and dissect differentially expressed genes in cases with clear cell renal cell melanoma (ccRCC). The epigenetic hand is closely associated with cell adhesion, the notch signaling system, axon guidance, and the thyroid hormone signaling pathway. The high- threat group showed enrichment in signaling pathways similar as p53, nod- suchlike receptor, and cytosolic DNA seeing, while the low- threat group was amended in pathways like adipose acid metabolism, PPAR signaling, and renin- angiotensin system.[57]

DISCUSSION

Radiomic analysis is a non-invasive method that can provide quantitative metrics that capture the heterogeneity of tumors and can be correlated with genomic data. It seeks to comprehend the link between imaging characteristics and molecular abnormalities discovered in tissue samples. As a result, has the ability to give beneficial insights into the diagnosis of cancer, therapy response evaluation, and patient outcome prediction. In contrast, traditional methods in cancer research often rely on histopathology and genomic

testing as standards of reference which involves the examination of tissue samples under a microscope and the analysis of genetic alterations.[5] The limitations of radiogenomics include the small cohort size, limited ability to validate findings using public data, heterogeneity of the cohort, reliance on a single center, and sensitivity to variations in imaging and segmentation protocols.[58]

Radiogenomic biomarkers have disadvantages, including the significant variability of genomic and imaging traits, which can make data integration difficult. Furthermore, the diversity of analytic methodologies, impact size, and direction of relationships are not always disclosed, which might influence how the results are interpreted. Different research groups may use different methods for feature extraction and analysis, leading to inconsistent results. This inconsistency hinders the validation and generalizability of radiomic models.[29] Radiomic characteristics are retrieved from segmented tumor pictures that are often outlined manually or semi-automatically by a human operator. This technique is subjective and prone to inter-observer variability, which might have an influence on radiomic feature correctness and repeatability. [45] Furthermore, the reproductibility of quantitative parameters used in radiogenomic analysis are majorly influenced by scanner systems and software packages. Radiomics has a limited repeatability owing to inconsistent radiomic analysis methodologies. A lack of adjustment of the acquisition settings may potentially impair the reliability and repeatability of the radiomic characteristics retrieved from imaging modalities.[10] There are presently no established protocols or software tools for extracting radiomic features. Different software programs may extract distinct sets of radiomic characteristics, making it difficult to evaluate and duplicate results across models. This limits the external validity of the models and hinders the identification of consistent radiomic features.[45] Methods must be standardized and validated in separate cohorts to guarantee radiogenomic biomarker reliability and generalizability. There may also be publication bias toward noteworthy discoveries, however the novelty of the topic of study mitigates this danger. [6] There is currently a lack of standardized protocols and methodologies for radiomic analysis in gliomas making it difficult to compare results across varies studies and limits the reliability and reproducibility of radiomic findings.[29]

Insufficient patient numbers make it difficult to draw clear conclusions, and other research with bigger sample sizes may be required to corroborate the findings.[12] Most models could not account for intra-tumoral heterogeneity, which refers to the occurrence of various clinical manifestations and genetic profiles in different parts of a tumor. Treating the entire tumor territory as a single homogenous entity may not properly anticipate the tumor's molecular profile or its related clinical consequences. [45] Heterogeneity in terms of imaging methods and genetic assays used, making it challenging to conduct a meta-analysis on the information.[59] Many radiomic studies in glioma management have been conducted on small and homogeneous study populations limiting the generalizability of the discoveries to a broader patient population. Radiomic analysis depends on the withdrawal of quantitative data from radiological images. However, the accuracy of these measurements can be affected by sampling errors, especially in cases where

the tumor is heterogeneous or the region of interest is not well-defined.[29] To further validate the findings, larger sample numbers and rigorous investigations are necessary to assess the usefulness, repeatability of radiomics biomarkers, and confirmation of prospective cohorts. [10] Most of the predictive models were developed based on relatively minor cohorts, often utilizing the same openly obtainable cohort (TCGA-KIRC). This raises concerns about overfitting the models to a specific cohort and limits the generalizability of the findings.[45]

Radiogenomics relies on the vacuity of high- quality imaging data and genomic information. still, carrying large and different datasets with comprehensive genomic biographies can be grueling, limiting the development and confirmation of robust radiogenomic models.[60] Lung cancer is a complex complaint with multiple inheritable differences and molecular pathways involved. Radiogenomic models frequently concentrate on specific inheritable mutations or pathways, which may not capture the full complexity of the complaint. also, the relationship between radiological features and genomic differences isn't always straightforward, making it challenging to establish clear associations.[61] Radiomics can give precious information about the excrescence characteristics, but it cannot replace the need for molecular and histopathological assessment as it may not capture all the molecular differences and histological features that are important for accurate opinion and treatment planning.[29] While radiogenomics has shown pledge in prognosticating treatment response and prognostic, its clinical mileage and integration into routine practice are still limited. There's a need for prospective confirmation studies and scientific trials to validate the clinical applicability and effectiveness of radiogenomic biomarkers.[35] The quality of CT studies can be told by colorful specialized factors similar as a CT scanner, accession mode, and voxel renovation algorithms which affect the value of the uprooted radiomic data and potentially introduce bias or variability.[45] Radiogenomic models frequently calculate on machine literacy algorithms, which can be considered" black boxes" in terms of understanding the underpinning mechanisms and features driving the prognostications. The lack of interpretability and explain ability of these models hinders their acceptance and trust among clinicians.[62] Radiogenomics primarily focuses on CT and PET imaging modalities, but integrating other imaging modalities, similar as MRI or molecular imaging, could give fresh precious information. still, the integration of multiple imaging modalities and their corresponding genomic data poses specialized and logistical challenges.[63] Although, There's a need for multi-center studies with larger and further different case populations to validate the effectiveness of radiomic analysis in clinical practice.[29] Addressing these limitations will be pivotal for the successful perpetration of radiogenomic biomarkers in clinical practice and substantiated patient care.[19] The field of radiogenomics in ccRCC is fairly immature, and utmost studies reviewed in the composition reckoned on retrospective analyses. Large-scale prospective studies are required for validating findings and establishing the therapeutic relevance of radiogenomics in ccRCC. Addressing these limitations is pivotal for the dependable use of radiogenomics as an object in medical practice. farther exploration, standardization of protocols, and confirmation in independent cohorts are necessary to overcome these challenges and unleash the full eventuality of radiogenomics in ccRCC.[45]

CONCLUSION

In conclusion, radiogenomics is a fleetly evolving field that combines radiomics features uprooted from medical imaging with genomic data to ameliorate the discovery, opinion, and treatment of colorful types of cancer, including bone, lung, brain, and renal cancer.

In bone cancer, radiogenomics has shown pledge in bracket, discriminational opinion, and prognostic by integrating imaging features with genomic data. colorful imaging modalities similar as glamorous resonance imaging (MRI), discrepancy- enhanced ultrasound (CEUS), and reckoned tomography (CT) are used to prize radiomic features that can separate molecular groups and excrescence molecular biomarkers. MRI, in particular, is largely salutary for screening bone cancer as it has advanced perceptivity than mammography and ultrasound. Radiogenomics in bone cancer focuses on generating imaging surrogates for genomic signatures and combining imaging, genomic, and molecular data to produce customized biomarkers for characterization of the complaint.[10]

Non-small cell lung cancer (NSCLC) is the most frequent kind of lung cancer, accounting for approximately 80–85 percent of all occurrences. Radiogenomics has the implicit to guide substantiated patient care in lung cancer by furnishing precious prognostic information by assaying the correlation between gene expressions and reckoned tomography (CT) and positron emigration tomography (PET) image features, experimenters have linked statistically significant pairwise correlations which have handed perceptivity into the prognostic significance of certain imaging features similar as excrescence size, edge shape, and sharpness. Accurate opinion of lung cancer is pivotal for carrying the cancer, prognosticating issues, and determining the most applicable treatment approach.[19]

Gliomas are primary brain excrescences, and radiogenomics has a wide range of operations in their operation. Radiomics and radiogenomics workflows and descriptors are used insub-visual MR image processing to offer precise opinion, prognosticate prognostic, and assess excrescence response to treatment. prolixity- ladened MRI (DW MRI) and other imaging ways can distinguish between benign and nasty renal lesions. Intravoxel incoherent stir (IVIM) analysis with a biexponential wind fit is a potential method for determining the pathological grade of clear cell renal cell melanoma. Machine literacy algorithms have been used to dissect radiomics features and prognosticate clinical issues in renal cancer, showing good discrimination capacities for overall survival, progression-free survival (PFS), and metastasis vaticination.[29]

The most frequent kind of renal cancer is clear cell renal cell melanoma (CCRCC). The stylish individual styles for ccRCC include imaging ways similar as reckoned tomography (CT) reviews and resonance imaging (MRI) which provides detailed evidence about the size, position, and characteristics of the excrescence, allowing for accurate opinion and staging. also, dynamic discrepancy- enhanced MRI and positron emigration tomography/ reckoned tomography (PET/ CT) with specific radiopharmaceuticals can

prop in secerning between benign and nasty renal lesions and assessing the extent of the complaint hence, playing a pivotal part in guiding treatment opinions and prognosticating patient issues in ccRCC.[45]

It's important to note that while radiogenomics shows pledge in perfecting prognostic, there are limitations that need to be addressed. These involves the requirement for larger and further different datasets, calibration of imaging protocols and analysis styles, reproducibility of results, addressing the natural complexity of the conditions, and conducting prospective confirmation studies and medical trials to illustrate the clinical applicability and effectiveness of radiogenomic biomarkers, the interpretability and explainability of radiogenomic models, as well as the integration of multiple imaging modalities, pose challenges that need to be overcome for successful perpetration in clinical practice. Despite these challenges, radiogenomics has the implicit to guide substantiated patient care and ameliorate the effectiveness of cancer treatment by furnishing precious perceptivity into excrescence geste, treatment response, and patient issues. farther exploration and development are demanded to overcome these obstacles and realize the full eventuality of radiogenomics in perfection oncology.

REFERENCES:

1) Li, S. and Zhou, B., 2022. A review of radiomics and genomics applications in cancers: the way towards precision medicine. *Radiation Oncology*, *17*(1), pp.1-10.

2)Pinker, K., Shitano, F., Sala, E., Do, R.K., Young, R.J., Wibmer, A.G., Hricak, H., Sutton, E.J. and Morris, E.A., 2018. Background, current role, and potential applications of radiogenomics. *Journal of Magnetic Resonance Imaging*, *47*(3), pp.604-620.

3) Lo Gullo, R., Daimiel, I., Morris, E.A. and Pinker, K., 2020. Combining molecular and imaging metrics in cancer: radiogenomics. *Insights into imaging*, *11*, pp.1-17.

4) Bakr, S., Gevaert, O., Echegaray, S., Ayers, K., Zhou, M., Shafiq, M., Zheng, H., Benson, J.A., Zhang, W., Leung, A.N. and Kadoch, M., 2018. A radiogenomic dataset of non-small cell lung cancer. *Scientific data*, *5*(1), pp.1-9.

5) Sala, E., Mema, E., Himoto, Y., Veeraraghavan, H., Brenton, J.D., Snyder, A., Weigelt, B. and Vargas, H.A., 2017. Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. *Clinical radiology*, *72*(1), pp.3-10.

6) Jansen, R.W., van Amstel, P., Martens, R.M., Kooi, I.E., Wesseling, P., de Langen, A.J., Menke-Van der Houven, C.W., Jansen, B.H., Moll, A.C., Dorsman, J.C. and Castelijns, J.A., 2018. Non-invasive tumor

genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. *Oncotarget*, *9*(28), p.20134.

7) Boca, I., Ciurea, A.I., Ciortea, C.A. and Dudea, S.M., 2021. Pros and cons for automated breast ultrasound (ABUS): a narrative review. *Journal of Personalized Medicine*, *11*(8), p.703.Boca, I., Ciurea, A.I., Ciortea, C.A. and Dudea, S.M., 2021. Pros and cons for automated breast ultrasound (ABUS): a narrative review. *Journal of Personalized Medicine*, *11*(8), p.703.

8) Lee, S.R., 2021. Surgery for fibroadenoma arising from axillary accessory breast. *BMC Women's Health*, *21*(1), pp.1-8.Lee, S.R., 2021.

Surgery for fibroadenoma arising from axillary accessory breast. *BMC Women's Health*, *21*(1), pp.1-8.

9) Ab Mumin, N., Hamid, M.T.R., Wong, J.H.D., Rahmat, K. and Ng, K.H., 2022. Magnetic resonance imaging phenotypes of breast cancer molecular subtypes: a systematic review. *Academic radiology*, *29*, pp.S89-S106.

10) Darvish, L., Bahreyni-Toossi, M.T., Roozbeh, N. and Azimian, H., 2022. The role of radiogenomics in the diagnosis of breast cancer: A systematic review. *Egyptian Journal of Medical Human Genetics*, *23*(1), pp.1-16.

11) Niu, Z., Xiao, M., Ma, L., Qin, J., Li, W., Zhang, J., Zhu, Q. and Jiang, Y., 2022. The value of contrast-enhanced ultrasound enhancement patterns for the diagnosis of sentinel lymph node status in breast cancer: systematic review and meta-analysis. *Quantitative Imaging in Medicine and Surgery*, *12*(2), p.936.

12) Yamamoto, S., Maki, D.D., Korn, R.L. and Kuo, M.D., 2012. Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. *American Journal of Roentgenology*, *199*(3), pp.654-663.

13) Ming, W., Zhu, Y., Bai, Y., Gu, W., Li, F., Hu, Z., Xia, T., Dai, Z., Yu, X., Li, H. and Gu, Y., 2022. Radiogenomics analysis reveals the associations of dynamic contrast-enhanced–MRI features with gene expression characteristics, PAM50 subtypes, and prognosis of breast cancer. *Frontiers in Oncology*, *12*, p.943326.

14) McCarthy, A.M., Friebel-Klingner, T., Ehsan, S., He, W., Welch, M., Chen, J., Kontos, D., Domchek, S.M., Conant, E.F., Semine, A. and Hughes, K., 2021. Relationship of established risk factors with breast cancer subtypes. *Cancer medicine*, *10*(18), pp.6456-6467.

15) Gallivanone, F., Bertoli, G. and Porro, D., 2022. Radiogenomics, Breast Cancer Diagnosis and Characterization: Current Status and Future Directions. *Methods and Protocols*, *5*(5), p.78.

16) Šutić, M., Vukić, A., Baranašić, J., Försti, A., Džubur, F., Samaržija, M., Jakopović, M., Brčić, L. and Knežević, J., 2021. Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management. *Journal of personalized medicine*, *11*(11), p.1102.

17) Czarnecka-Kujawa, K. and Yasufuku, K., 2017. The role of endobronchial ultrasound versus mediastinoscopy for non-small cell lung cancer. *Journal of Thoracic Disease*, *9*(Suppl 2), p.S83.

18) Bouget, D., Jørgensen, A., Kiss, G., Leira, H.O. and Langø, T., 2019. Semantic segmentation and detection of mediastinal lymph nodes and anatomical structures in CT data for lung cancer staging. *International journal of computer assisted radiology and surgery*, *14*, pp.977-986.

19)Anagnostopoulos, A.K., Gaitanis, A., Gkiozos, I., Athanasiadis, E.I., Chatziioannou, S.N., Syrigos, K.N., Thanos, D., Chatziioannou, A.N. and Papanikolaou, N., 2022. Radiomics/radiogenomics in lung cancer: basic principles and initial clinical results. *Cancers*, *14*(7), p.1657.

20) Malafaia, M., Pereira, T., Silva, F., Morgado, J., Cunha, A. and Oliveira, H.P., 2021, November. Ensemble strategies for EGFR mutation status prediction in lung cancer. In *2021 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)* (pp. 3285-3288). IEEE

21) Zhang, F., Wu, X., Zhu, J., Huang, Y., Song, X. and Jiang, L., 2021. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, pp.1-10.

22) Kim, G., Kim, J., Cha, H., Park, W.Y., Ahn, J.S., Ahn, M.J., Park, K., Park, Y.J., Choi, J.Y., Lee, K.H. and Lee, S.H., 2020. Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. *Scientific reports*, *10*(1), p.13231.

23) Jin, X., Guan, Y., Zhang, Z. and Wang, H., 2020. Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer. *BMC cancer*, *20*(1), pp.1-10.

24) Chen, Y.J., Guo, Y.N., Shi, K., Huang, H.M., Huang, S.P., Xu, W.Q., Li, Z.Y., Wei, K.L., Gan, T.Q. and Chen, G., 2019. Down-regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: a comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data. *Respiratory research*, *20*, pp.1-18.

25) Abdu-Aljabar, R.D.A. and Awad, O.A., 2021, February. A Comparative analysis study of lung cancer detection and relapse prediction using XGBoost classifier. In *IOP conference series: materials science and engineering* (Vol. 1076, No. 1, p. 012048). IOP Publishing.

26) Maynard, A., McCoach, C.E., Rotow, J.K., Harris, L., Haderk, F., Kerr, D.L., Elizabeth, A.Y., Schenk, E.L., Tan, W., Zee, A. and Tan, M., 2020. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. *Cell*, *182*(5), pp.1232-1251.

27) Tan, A.C., Teh, Y.L., Lai, G.G. and Tan, D.S., 2019. Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC). *Expert Review Of Anticancer Therapy*, *19*(6), pp.431-435.

28) Ahir, B.K., Engelhard, H.H. and Lakka, S.S., 2020. Tumor development and angiogenesis in adult brain tumor: glioblastoma. *Molecular neurobiology*, *57*, pp.2461-2478.

29) Singh, G., Manjila, S., Sakla, N., True, A., Wardeh, A.H., Beig, N., Vaysberg, A., Matthews, J., Prasanna, P. and Spektor, V., 2021. Radiomics and radiogenomics in gliomas: a contemporary update. *British journal of cancer*, *125*(5), pp.641-657.

30) Beig, N., Patel, J., Prasanna, P., Hill, V., Gupta, A., Correa, R., Bera, K., Singh, S., Partovi, S., Varadan, V. and Ahluwalia, M., 2018. Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. *Scientific reports*, *8*(1), p.7.

31) Lin, W., Wu, S., Chen, X., Ye, Y., Weng, Y., Pan, Y., Chen, Z., Chen, L., Qiu, X. and Qiu, S., 2020. Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma groups. *Frontiers in oncology*, *10*, p.796.

32) Xu, S., Tang, L., Liu, Z., Luo, C. and Cheng, Q., 2021. Hypoxia-related lncRNA correlates with prognosis and immune microenvironment in lower-grade glioma. *Frontiers in Immunology*, *12*, p.731048.

33) Lo, C.M., Chen, Y.C., Weng, R.C. and Hsieh, K.L.C., 2019. Intelligent glioma grading based on deep transfer learning of MRI radiomic features. *Applied Sciences*, *9*(22), p.4926.

34) Yan, J., Zhang, B., Zhang, S., Cheng, J., Liu, X., Wang, W., Dong, Y., Zhang, L., Mo, X., Chen, Q. and Fang, J., 2021. Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients. *NPJ Precision Oncology*, *5*(1), p.72.

35) Fathi Kazerooni, A., Bagley, S.J., Akbari, H., Saxena, S., Bagheri, S., Guo, J., Chawla, S., Nabavizadeh, A., Mohan, S., Bakas, S. and Davatzikos, C., 2021. Applications of radiomics and radiogenomics in high-grade gliomas in the era of precision medicine. *Cancers*, *13*(23), p.5921.

36) Gatto, L., Franceschi, E., Tosoni, A., Di Nunno, V., Tonon, C., Lodi, R., Agati, R., Bartolini, S. and Brandes, A.A., 2022. Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. *Biomedicines*, *10*(12), p.3205.

37) Qian, Z., Li, Y., Sun, Z., Fan, X., Xu, K., Wang, K., Li, S., Zhang, Z., Jiang, T., Liu, X. and Wang, Y., 2018. Radiogenomics of lower-grade gliomas: a radiomic signature as a biological surrogate for survival prediction. *Aging (Albany NY)*, *10*(10), p.2884.

38) Shen, N., Zhang, S., Cho, J., Li, S., Zhang, J., Xie, Y., Wang, Y. and Zhu, W., 2021. Application of cluster analysis of time evolution for magnetic resonance imaging-derived oxygen extraction fraction mapping: a promising strategy for the genetic profile prediction and grading of glioma. *Frontiers in Neuroscience*, *15*, p.736891.

39) Wu, H., Tong, H., Du, X., Guo, H., Ma, Q., Zhang, Y., Zhou, X., Liu, H., Wang, S., Fang, J. and Zhang, W., 2020. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas. *European Radiology*, *30*, pp.3254-3265.

40) Stumpo, V., Guida, L., Bellomo, J., Van Niftrik, C.H.B., Sebök, M., Berhouma, M., Bink, A., Weller, M., Kulcsar, Z., Regli, L. and Fierstra, J., 2022. Hemodynamic Imaging in Cerebral Diffuse Glioma—Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions. *Cancers*, *14*(5), p.1342.

41) Prasanna, P., Mitra, J., Beig, N., Nayate, A., Patel, J., Ghose, S., Thawani, R., Partovi, S., Madabhushi, A. and Tiwari, P., 2019. Mass effect deformation heterogeneity (MEDH) on gadolinium-contrast T1-weighted MRI is associated with decreased survival in patients with right cerebral hemisphere glioblastoma: a feasibility study. *Scientific reports*, *9*(1), p.1145.

42) Tunç, B., Hormuth II, D.A., Biros, G. and Yankeelov, T.E., 2021. Modeling of glioma growth with mass effect by longitudinal magnetic resonance imaging. *IEEE Transactions on Biomedical Engineering*, *68*(12), pp.3713-3724.

43) Bhargav, A.G., Domino, J.S., Chamoun, R. and Thomas, S.M., 2022. Mechanical properties in the glioma microenvironment: Emerging insights and theranostic opportunities. *Frontiers in Oncology*, *11*, p.805628.

44) Ferro, M., Musi, G., Marchioni, M., Maggi, M., Veccia, A., Del Giudice, F., Barone, B., Crocetto, F., Lasorsa, F., Antonelli, A. and Schips, L., 2023. Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects. *International journal of molecular sciences*, *24*(5), p.4615.

45) Khaleel, S., Katims, A., Cumarasamy, S., Rosenzweig, S., Attalla, K., Hakimi, A.A. and Mehrazin, R., 2022. Radiogenomics in clear cell renal cell carcinoma: A review of the current status and future directions. *Cancers*, *14*(9), p.2085.

46) Zeng, H., Chen, L., Wang, M., Luo, Y., Huang, Y. and Ma, X., 2021. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma. *Aging (Albany NY)*, *13*(7), p.9960.

47) Schulz, S., Woerl, A.C., Jungmann, F., Glasner, C., Stenzel, P., Strobl, S., Fernandez, A., Wagner, D.C., Haferkamp, A., Mildenberger, P. and Roth, W., 2021. Multimodal deep learning for prognosis prediction in renal cancer. *Frontiers In oncology*, *11*, p.788740.

48) Zhang, G., Wu, Y., Zhang, J., Fang, Z., Liu, Z., Xu, Z. and Fan, Y., 2018. Nomograms for predicting long-term overall survival and disease-specific survival of patients with clear cell renal cell carcinoma. *OncoTargets and therapy*, pp.5535-5544.

49) Hekman, Marlène CH, Mark Rijpkema, Erik H. Aarntzen, Sasja F. Mulder, Johan F. Langenhuijsen, Egbert Oosterwijk, Otto C. Boerman, Wim JG Oyen, and Peter FA Mulders. "Positron emission tomography/computed tomography with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion." *European Urology* 74, no. 3 (2018): 257-260.

50) Rizzo, A., Racca, M., Dall'Armellina, S., Rescigno, P., Banna, G.L., Albano, D., Dondi, F., Bertagna, F., Annunziata, S. and Treglia, G., 2023. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. *Cancers*, *15*(2), p.355.

51) Nikpanah, M., Paschall, A.K., Ahlman, M.A., Civelek, A.C., Farhadi, F., Mirmomen, S.M., Li, X., Saboury, B., Ball, M.W., Merino, M.J. and Srinivasan, R., 2021. 18 Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. *Abdominal Radiology*, *46*, pp.3301-3308.

52) Farhadi, F., Nikpanah, M., Paschall, A.K., Shafiei, A., Tadayoni, A., Ball, M.W., Linehan, W.M., Jones, E.C. and Malayeri, A.A., 2020. Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel–Lindau Disease. *Radiology*, *295*(3), pp.583-590.

53) Zhu, Q., Zhu, W., Wu, J., Chen, W., Ye, J. and Ling, J., 2022. Comparative study of conventional diffusion-weighted imaging and introvoxel incoherent motion in assessment of pathological grade of clear cell renal cell carcinoma. *The British Journal of Radiology*, *95*(1133), p.20210485.

54) Gao, J., Ye, F., Han, F., Jiang, H. and Zhang, J., 2022. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma. *Frontiers in immunology*, *13*, p.956679.

55) Bao, M., Shi, R., Zhang, K., Zhao, Y., Wang, Y. and Bao, X., 2019. Development of a membrane lipid metabolism–based signature to predict overall survival for personalized medicine in ccRCC patients. *Epma Journal*, *10*, pp.383-393.

56) Wu, J., Jin, S., Gu, W., Wan, F., Zhang, H., Shi, G., Qu, Y. and Ye, D., 2019. Construction and validation of a 9-gene signature for predicting prognosis in stage III clear cell renal cell carcinoma. *Frontiers in oncology*, *9*, p.152.

57) Wang, Y., Chen, L., Ju, L., Qian, K., Wang, X., Xiao, Y. and Wang, G., 2020. Epigenetic signature predicts overall survival clear cell renal cell carcinoma. *Cancer Cell International*, *20*(1), pp.1-13.

58) Spielvogel, C.P., Stoiber, S., Papp, L., Krajnc, D., Grahovac, M., Gurnhofer, E., Trachtova, K., Bystry, V., Leisser, A., Jank, B. and Schnoell, J., 2023. Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, *50*(2), pp.546-558.

59) Fan, M., Xia, P., Clarke, R., Wang, Y. and Li, L., 2020. Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer. *Nature communications*, *11*(1), p.4861.

60) Nair, J.K.R., Saeed, U.A., McDougall, C.C., Sabri, A., Kovacina, B., Raidu, B.V.S., Khokhar, R.A., Probst, S., Hirsh, V., Chankowsky, J. and Van Kempen, L.C., 2021. Radiogenomic models using machine learning techniques to predict EGFR mutations in non-small cell lung cancer. *Canadian Association of Radiologists Journal*, *72*(1), pp.109-119.

61) Kirienko, M., Sollini, M., Corbetta, M., Voulaz, E., Gozzi, N., Interlenghi, M., Gallivanone, F., Castiglioni, I., Asselta, R., Duga, S. and Soldà, G., 2021. Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer. *European journal of nuclear medicine and molecular imaging*, *48*, pp.3643-3655.

62) Coates, J.T., Pirovano, G. and El Naqa, I., 2021. Radiomic and radiogenomic modeling for radiotherapy: strategies, pitfalls, and challenges. *Journal of Medical Imaging*, *8*(3), pp.031902-031902.

63) Seow, P., Wong, J.H.D., Ahmad-Annuar, A., Mahajan, A., Abdullah, N.A. and Ramli, N., 2018. Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review. *The British journal of radiology*, *91*(1092), p.20170930.


JETIR